Clinical Guest Contributors

  1. Don't Accept This Site-Level Start-Up Bottleneck— Instead, Learn How To Stop It 8/10/2026

    Combining investigator meetings and SIVs can cut site activation timelines in half — if sponsors build a compliance-sound case and involve QA early.

  2. What It Takes To Validate A Biomarker For Real-World, Post-Transplant Care 8/7/2026

    Yelena Bushman, MBA, VP of cell therapy and transplant at CareDx, discusses the operational challenges of validating biomarkers for post-transplant care.

  3. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  4. C-Suite Changes Help Biotech Narrow Focus But Maintain Drive To Treat Fatal Neonatal Brain Injury 8/5/2026

    Newly-appointed leaders at ReAlta Life Sciences discuss their skill sets, their goals for advancing a therapy for hypoxic ischemic encephalopathy (HIE), and how they keep momentum as they strive to help bring this potentially lifesaving therapy to market.

  5. 3 Ways To Solve Data Friction In Modern Clinical Data Management 8/4/2026

    Senior clinical data manager Shasidar Reddy Abbidi shares how to reduce data friction with targeted automation, early standards adoption, and clearer workflows that move data to decisions faster.

  6. How Visible Is Your Clinical Trial To AI? 8/3/2026

    Ross Jacksons explores how clinical trials show up — it at all — in AI tools and what that means for sponsors' approach to publicizing trial information.

  7. Threat From Within: Why Biopharma's Drug Development Bottleneck Is Systemic 7/30/2026

    As FDA timelines and AI-enabled development accelerate, biopharma’s biggest bottleneck may be its own ability to make earlier, cross-functional decisions.

  8. Beyond Task Tracking: Why ClinOps Needs Dependency Intelligence 7/29/2026

    Clinical trial operations will always need task tracking, but they're not enough on their own. Dependency intelligence shifts the focus toward readiness not reaction.

  9. To Take On Transverse Myelitis, Researchers Must First Address Heterogeneity And Misguided Outcome Measures 7/29/2026

    UNC researcher Irena Dujmovic Basuroski, MD, Ph.D., discusses why transverse myelitis remains difficult to study, how multicenter collaboration and adaptive trial designs may help, and why better clinical, patient-reported, and biomarker-based measures are essential to advancing treatment.

  10. From Signal To Strategy: What Oncology Basket Trials Can Teach Clinical Development Teams 7/29/2026

    AbbVie's Svetlana Kobina discusses how basket trials can help clinical development teams move from early clinical signals to a more disciplined strategy.